This is a mono-center observational ambispective study in which adult patients with congenital heart disease evaluated at our institution will be enrolled.
The primary endopoint is to assess the clinical and echocardiographic predictors of adverse events during follow-up (death, arrhythmias, cardiac hospitalization).
The secondary endpoints are: 1) evaluation of the incidence of the singular components of the primary endpoint; 2) evaluation of the prognostic impact of acquired lesions, including valve disease not present at birth; 3) need for surgical/percutaneous interventions during follow up.
Participants will be evaluated in the context of scheduled follow-up visits in our Outpatient ACHD Clinic. No interventions/drug administration will be performed other than those required by standard clinical practice.
Patients evaluated in our ACHD Outpatient Clinic between January 2014 and December 2026
Age ≥ 18 years
Patients without congenital heart disease confirmed during the first evaluation
Impossibility to retrieve information about the first clinical evaluation in our clinic from our electonic datasets
Follow up shorter than one-year
Refused consent to participate to the study.